Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  07:59:15 2023-06-08 pm EDT
160.70 USD   +0.27%
09:29aJohnson & Johnson Releases its 2022 Health for Humanity Report and We All Belong, 2022 DEI Impact Review
AQ
09:12aJohnson & Johnson Releases 2022 Health for Humanity Report Demonstrating Progress Against Goals
AQ
03:55aJohnson & Johnson Health Care Systems Gets Up to $47.3 Million US Defense Logistics Agency Contract
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about JOHNSON & JOHNSON
09:29aJohnson & Johnson Releases its 2022 Health for Humanity Report and We All Belong, 2022 ..
AQ
09:12aJohnson & Johnson Releases 2022 Health for Humanity Report Demonstrating Progress Again..
AQ
03:55aJohnson & Johnson Health Care Systems Gets Up to $47.3 Million US Defense Logistics Age..
MT
06/07Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to U.S. FDA..
PU
06/07Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval..
AQ
06/06Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
BU
06/06Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seekin..
CI
06/06Advancing Multiple Shots On Clinical Goals, Coeptis Therapeutics Positions For A Busy V..
AQ
06/05Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progress..
PU
06/05Johnson & Johnson Announces Long-Term Data from the Pivotal Phase 1/2 Majestec-1 Study
CI
06/05The Janssen Pharmaceutical Companies of Johnson & Johnson Announces Results from the Ph..
CI
06/05Johnson & Johnson Unit Recalls Impella Heart Pump, US FDA Designates Class 1 Recall Ord..
MT
06/05Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Sho..
PU
06/05Johnson & Johnson : Janssen Presents First-Ever Results from Dual Bispecific Combination S..
PU
06/05Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progre..
AQ
More most relevant news
All news about JOHNSON & JOHNSON
09:29aJohnson & Johnson Releases its 2022 Health for Humanity Report and We All Belong, 2022 ..
AQ
09:12aJohnson & Johnson Releases 2022 Health for Humanity Report Demonstrating Progress Again..
AQ
03:55aJohnson & Johnson Health Care Systems Gets Up to $47.3 Million US Defense Logistics Age..
MT
06/07Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to U.S. FDA..
PU
06/07Indices: Flight to quality
MS
06/07Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval..
AQ
06/06Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
BU
06/06Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seekin..
CI
06/06Alkermes Gets Final Award in Janssen Pharmaceutica Arbitration; 2023 Adjusted EPS, Reve..
MT
06/06Advancing Multiple Shots On Clinical Goals, Coeptis Therapeutics Positions For A Busy V..
AQ
More news
News in other languages on JOHNSON & JOHNSON
03:55aJohnson & Johnson Health Care Systems obtient un contrat de 47,3 millions de dollars de..
06/06Johnson & Johnson soumet à la FDA une demande d'autorisation de mise sur le marché supp..
06/06Indizes: Fly to quality
06/06J&J : des résultats prometteurs pour Carvykti
06/06Alkermes reçoit la sentence finale dans l'arbitrage de Janssen Pharmaceutica ; révision..
06/06J&J : présente des données à plus long terme sur Tecvayli
06/06J&J : résultats encourageants pour le Balversa
06/06Indices : Fly to quality avec une fusée
06/05Rubrik, soutenue par Microsoft, engage des banques pour son introduction en bourse -sou..
06/05Johnson & Johnson annonce les données à long terme de l'étude pivotale de phase 1/2 Maj..
More news
Analyst Recommendations on JOHNSON & JOHNSON
05/30Kenvue Initiated at Outperform by RBC, Price Target Set at $29 as Firm Highlights Johns..
MT
04/20UBS Adjusts Johnson & Johnson Price Target to $177 From $164, Maintains Neutral Rating
MT
04/19Atlantic Equities Trims Price Target on Johnson & Johnson to $167 From $168, Keeps Neut..
MT
04/19Bernstein Adjusts Price Target on Johnson & Johnson to $176 From $173, Keeps Market Per..
MT
04/19Raymond James Adjusts Price Target on Johnson & Johnson to $181 From $185, Keeps Outper..
MT
More recommendations
Press releases
09:29aJohnson & Johnson Releases its 2022 Health for Humanity Report and We All Belong, 2022 ..
AQ
09:12aJohnson & Johnson Releases 2022 Health for Humanity Report Demonstrating Progress Again..
AQ
06/07Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to U.S. FDA..
PU
06/07Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval..
AQ
06/06Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
BU
More press releases
Upcoming event on JOHNSON & JOHNSON
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer